Evidence map›Paper›PMID 41037651›Full record

ReviewEndocrine, metabolic & immune disorders drug targets2026

Improving Immune Checkpoint Therapy in the Tumor Microenvironment by Targeting T Cell Metabolism.

Jun Wei, Baozhen An, Renchao Dong, Xinyi Tu, Yifei Dong, Yuang Liu, Yanqiu Liu

Abstract readReview
In one paragraph

Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun WeiShandong University of Traditional Chinese Medicine, Jinan, China.
Baozhen AnThe First Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Renchao DongShandong University of Traditional Chinese Medicine, Jinan, China.
Xinyi TuShandong University of Traditional Chinese Medicine, Jinan, China.
Yifei DongShandong University of Traditional Chinese Medicine, Jinan, China.
Yuang LiuShandong University of Traditional Chinese Medicine, Jinan, China.
Yanqiu LiuShandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To meet the increased nutrient requirements associated with rapid cellular proliferation, tumor cells undergo metabolic reprogramming, characterized by a substantial increase in the production of energy and precursor molecules necessary for biosynthetic processes. Similarly, T cells experience metabolic reprogramming to support their proliferation and immunological functions, leading to metabolic competition with tumor cells within the tumor microenvironment (TME). This metabolic competition adversely affects T cell activation, proliferation, and immune function, primarily due to the limited availability of glucose, lipids, and amino acids. Furthermore, cytokines and immune checkpoints significantly impact T cell-mediated immunoreactivity. Modulating the metabolism of tumor cells and T cell-mediated immune evasion within the TME is of paramount importance. Notably, the metabolism of small-molecule target agents has garnered considerable attention in the context of the TME. This study aimed to examine the influence of various microenvironmental factors on T cell metabolism and explore corresponding innovative therapeutic approaches, thereby offering a comprehensive array of potential clinical strategies for cancer prevention and treatment.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyNeoplasmsT-LymphocytesTumor MicroenvironmentAnimalsHumansMetabolic ReprogrammingImmune Checkpoint Inhibitorscombination therapyimmune checkpointnutrient competitionT cell metabolismtumor immunotherapyTumor microenvironment

Identifiers

PMID41037651
PMCPMC13662720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.